Incretin hormones - An update

Scandinavian Journal of Clinical and Laboratory Investigation, Supplement

Volumn 61, Issue 234, 2001, Pages 75-85

  Holst, J J ^a   Orskov C ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Beta cell growth; Dipeptidyl peptidase IV (DPP IV); Gastric emptying; Gastric inhibitory polypeptide; GIP; GLP 1; Glucagon; Glucagon like peptide 1; Glucose dependent insulinotropic polypeptide; Insulin secretion; Type 2 diabetes mellitus

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; METFORMIN; PEPTIDE HORMONE; UNCLASSIFIED DRUG; GLUCAGON; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1 (7 36)AMIDE; GLUCAGON-LIKE PEPTIDE 1 (7-36)AMIDE; INSULIN; PEPTIDE FRAGMENT; PROTEIN PRECURSOR;

APPETITE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONFERENCE PAPER; FEEDING; FOOD INTAKE; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HORMONE DETERMINATION; HUMAN; HYPERGLYCEMIA; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INTESTINE ABSORPTION; INTESTINE MUCOSA; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; STEM CELL; STOMACH EMPTYING; ANIMAL; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SECRETION;

RODENTIA;

ANIMALS; DIABETES MELLITUS, TYPE 2; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDES; GLUCOSE; HUMANS; INSULIN; INTESTINAL MUCOSA; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS;

EID: 0034740428     PISSN: 0085591X     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655101317095455     Document Type: Conference Paper

References (96)

1. Gastrointestinal hormones and insulin secretion
2. New interpretation of oral glucose tolerance
3. Contributions a l'etude des variation physiologiques de la secretion interne de pancreas: Relations entre les secretions externe et interne du pancreas
4. Gut signals for islet hormone release
5. Physiological augmentation of amino acid-induced insulin secretion by GIP and GLP-I but not by CCK-8
6. Entero-insular axis
7. New developments in the incretin concept
8. Neural regulation of pancreatic hormone secretion
9. Plasma insulin responses to oral and intravenous glucose: Studies in normal and diabetic subjects
10. Preserved incretin effect in type 1 diabetic patients with end- stage nephropathy treated by combined heterotopic pancreas and kidney transplantation
11. Oral glucose augmentation of insulin secretion: Interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels
12. Role of endogenously released cholecystokinin in determining postprandial insulin levels in man: Effects of loxiglumide, a specific cholecystokinin receptor antagonist
13. Antidiabetogenic action of cholecystokinin-8 in type 2 diabetes
14. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus
15. Cholecystokinin-A and cholecystokinin-B/gastrin receptor mRNA expression in the gastrointestinal tract and pancreas of the rat and man. A polymerase chain reaction study
16. Effect of secretin on basal- and glucose-stimulated insulin secretion in man
17. Reduced GLP-1 and insulin responses and glucose intolerance after gastric glucose in GRP receptor-deleted mice
18. VIP and PHI in the pig pancreas: Coexistence, corelease, and cooperative effects
19. PACAP-(1-38) as neurotransmitter in pig pancreas: Receptor activation revealed by the antagonist PACAP-(6-38)
20. Cell and molecular biology of the incretin hormones glucagonlike peptide-I and glucose-dependent insulin releasing polypeptide
21. Glucagon-like Peptide 1(GLP-1): An intestinal hormone signalling nutritional abundance, with an unusual therapeutic potential
22. Sequence of an intestinal cDNA encoding human gastric inhibitory polypeptide precursor
23. Immunoreactive gastric inhibitory polypeptide
24. Gastric inhibitory polypeptide receptor, a member of the secretin- vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain
25. Colocalization of GLP-1 and GIP in human and porcine intestine
26. Gastric Inhibitory Polypeptide
27. Glucagon-like peptide I and glucose-dependent insulinotropic polypeptide stimulate Ca2+-induced secretion in rat alpha-cells by a protein kinase A-mediated mechanism
28. Stimulation of insulin secretion by gastric inhibitory polypeptide in man
29. Depression of insulin release by anti-GIP serum after oral glucose in rats
30. Influence of gastric inhibitory polypeptide antiserum on glucose-induced insulin secretion in rats
31. Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat
32. Glucose intolerance caused by a defect in the entero-insular axis: A study in gastric inhibitory polypeptide receptor knockout mice
33. Glucose-dependent insulinotropic polypeptide confers early phase insulin release to oral glucose in rats: Demonstration by a receptor antagonist
34. Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: Interactions with glucose, phenylalanine, and cholecystokinin-8
35. Preservation of incretin activity after removal of gastric inhibitory polypeptide (GIP) from rat gut extracts by immunoadsorption
36. Gastric inhibitory polypeptide and insulin release in response to oral and intravenous glucose in coeliac disease
37. Gastric inhibitory polypeptide (GIP) and insulin release after small- bowel resection in man
38. GIP, incretin and gastrointestinal disease
39. Exon duplication and divergence in the human preproglucagon gene
40. Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing
41. Glucagon-like peptides GLP- 1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas
42. Oxyntomodulin (glicentin-(33-69)): Pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs
43. Molecular heterogeneity of glucagon in normal subjects and in patients with glucagon-producing tumours
44. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day
45. Glucagon-like peptide-1 7-36: A physiological incretin in man
46. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide.
47. Glucagon-like peptide-1 is a physiological incretin in rat
48. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene
49. Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice
50. Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha- glucosidase inhibition (acarbose)
51. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations
52. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, regulates fasting glycemia and nonenteral glucose clearance in mice
53. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo
54. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor
55. Dipeptidyl-peptidase IV (CD26) - Role in the inactivation of regulatory peptides
56. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig
57. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-l-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine
58. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow
59. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent- mediated central mechanisms
60. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1
61. Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms
62. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide
63. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes
64. Absence of incretin effect in obese type 2 and diminished effect in lean type 2 and obese subjects
65. Lack of germ-line mutations in the GIP-coding region of the pro-GIP in type II diabetic patients
66. Determinants of the impaired secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetic patients
67. Gut incretin hormones in identical twins discordant for non- insulin- dependent diabetes mellitus (NIDDM) - Evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins
68. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients
69. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-I (7-37) in normal and diabetic subjects
70. Identification of two missense mutations in the GIP receptor gene: A functional study and association analysis with NIDDM: No evidence of association with Japanese NIDDM subjects
71. Discovery of amino acid variants in the human glucose-dependent insulinotropic polypeptide (GIP) receptor: The impact on the pancreatic beta cell responses and functionel expression studies in Chinese hamster fibroblast cells
72. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients
73. Glucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent diabetes mellitus
74. Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects
75. Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells
76. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells
77. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats
78. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas
79. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells
80. Glucagon-like peptide-1 induces cell proliferation and pancreatic- duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats
81. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients
82. Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man
83. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man
84. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans
85. Roles of amylin in diabetes and in regulation of nutrient load
86. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans
87. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men
88. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2
89. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM
90. Effects of subcutaneous glucagon-like peptide I (GLP-1 [7-36 amide]) in patients with NIDDM
91. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects
92. Glucagon-like peptide-1, A gastrointestinal hormone with a pharmaceutical potential
93. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients
94. GLP-1 for six weeks reduces weight and improves insulin sensitivity and glycemic control in patients with type 2 diabetes
95. Additive glucose-lowering effects of glucagon-like peptide- 1 and metformin in type 2 diabetes
96. The U.K. Prospective diabetes study. A review